Who Paid My Doc
Quinn Kneifl
Physician Assistant, Medical Pender, NE Physician Assistant
NPI 1023063401 CMS profile 11188478
958 Wellness Way Ste 1, Pender, NE 68047
General payments
$1,661
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Quinn Kneifl of Pender, NE is reported in the CMS Open Payments database as having received $1,661 across 113 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $470 | 31 | |
| 2024 | General | $363 | 24 | |
| 2023 | General | $417 | 28 | |
| 2022 | General | $235 | 17 | |
| 2021 | General | $175 | 13 |
Beside peers
- Quinn Kneifl
- Physician Assistant, Medical median
- Middle half of Physician Assistant, Medical
- National median
In program year 2025, general payments to Quinn Kneifl were reported at $470. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.
Show as a table
| Year | Quinn Kneifl | Physician Assistant, Medical median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $61 | $19–$193 | $163 |
| 2020 | $0 | $20 | $14–$64 | $114 |
| 2021 | $175 | $156 | $41–$563 | $132 |
| 2022 | $235 | $185 | $55–$649 | $149 |
| 2023 | $417 | $199 | $58–$717 | $160 |
| 2024 | $363 | $206 | $62–$740 | $164 |
| 2025 | $470 | $214 | $62–$755 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 84 drugsPart D claims
3,288
Drug cost
$217,880
Branded share of claims
21.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 72 | $47,700 | |
| Ozempic Semaglutide | Brand | 33 | $31,733 | |
| Mounjaro Tirzepatide | Brand | 28 | $27,003 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 17 | $14,773 | |
| Rybelsus Semaglutide | Brand | 13 | $11,830 | |
| Trulicity Dulaglutide | Brand | 12 | $11,257 | |
| Xarelto Rivaroxaban | Brand | 25 | $10,326 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 18 | $9,886 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 13 | $7,317 | |
| Brilinta Ticagrelor | Brand | 12 | $5,484 |
The 10 drugs with the highest cost, of 84 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 13 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| LEQVIO |
|
$67 | — | — |
| ENTRESTO |
|
$67 | — | — |
| QULIPTA |
|
$45 | — | — |
| Veozah |
|
$35 | — | — |
| UBRELVY |
|
$26 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 13 in the dashboard with a free accountRecords
113 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physician Assistant, Medical in Nebraska
Michelle Sitzman
Physician Assistant, Medical · Lincoln, NE
Kaitlin Matthes
Physician Assistant, Medical · Lincoln, NE
Kelly Hoover
Physician Assistant, Medical · Omaha, NE
Lyndsey Degenhardt
Physician Assistant, Medical · Elkhorn, NE
Jacob Ridder
Physician Assistant, Medical · Omaha, NE
Angelika Stevens
Physician Assistant, Medical · Omaha, NE
Related records
Physician Assistant, Medical in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Physician Assistant, Medical
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.